RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

This study is testing a new, experimental drug called daraxonrasib to see if it can help treat pancreatic cancer that has spread to other parts of the body. Researchers want to find out if using this new drug alone or with standard chemotherapy works better than the current standard treatments.

This study is for adults aged 18 and older who have recently been diagnosed with metastatic pancreatic adenocarcinoma. You must be physically active and have had specific genetic testing on your tumor to confirm your eligibility.

Participants will be randomly assigned to one of three groups: receiving the new drug alone, receiving the new drug combined with chemotherapy, or receiving standard chemotherapy alone. You will need to attend regular clinic appointments so the medical team can monitor your health and how well the treatment is working.

The study is currently recruiting patients at medical centers in Tampa, Florida; Baltimore, Maryland; and Boston, Massachusetts. Participation requires a commitment to follow the study schedule and treatment plan.